We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

NT-proBNP Underestimates Heart Failure Risk for Certain Patients

By LabMedica International staff writers
Posted on 03 May 2022
Print article
Image: N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics (Photo courtesy of TCTMD)
Image: N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics (Photo courtesy of TCTMD)

The N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics, according to a cohort study suggesting the importance of sex and race in interpreting risk for people free of HF at baseline.

N-terminal pro B-type natriuretic peptide (NT-proBNP) is an inactive peptide released along with the active peptide hormone BNP when the walls of the heart are stretched or there is pressure overload on the heart e.g. by fluid overload. BNP then acts on the kidneys causing fluid and sodium loss in the urine and mild vasodilation so releasing the pressure.

Cardiologists at the Brigham and Women’s Hospital (Boston, MA, USA) and their colleagues wanted to determine whether physiologic determinants of NT-proBNP concentrations account for sex and race differences, and to more uniformly predict HF risk using NT-proBNP in these demographic subgroups. The team enrolled 5,191 individuals from visit five averaged 76.0 ± 5.2 years of age. Men and Black people each accounted for 41% and 20%, respectively, of the overall cohort. The contribution of clinical, anthropometric, echocardiographic, and laboratory parameters to sex- and race-based differences in NT-proBNP concentration was assessed at visit five using linear regression. Participants included were free of HF in midlife.

The investigators reported that the median (IQR) NT-proBNP concentration was 124 (64-239) pg/mL. In both midlife and late life, NT-proBNP concentration was lowest in Black men (median [IQR] concentration: visit 2, 30 [14-67] pg/mL; visit five, 74 [34-153] pg/mL) and highest in White women (median [IQR] concentration: visit 2, 70 [42-111] pg/mL; visit, five, 154 [82-268] pg/mL). Substantial differences in the absolute risk of incident HF or death existed across the sex- and race-based categories at any NT-proBNP concentration (e.g., 7-fold [rate ratio, 6.7] and 3-fold [rate ratio, 2.7] difference at visit two and visit five, respectively, at guideline-recommended thresholds) with higher risk consistently observed among Black men and lower risk in White women.

The authors concluded that in their study, sex- and race-based differences in NT-proBNP persisted after accounting for known physiologic determinants. Absolute risk associated with a given value of NT-proBNP varied substantially by sex and race. Consideration of NT-proBNP values in the context of sex and race allows for more uniform prediction of absolute risk across important demographic subgroups. The study was published on April 27, 2022 in the journal JAMA Cardiology.

Related Links:
Brigham and Women’s Hospital

Platinum Supplier
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Supplier
PCR Microplate
Semi-Auto Rotary Microtome
Fecal Bacterial Test
CLART EnteroBac

Print article


Molecular Diagnostics

view channel
Image: Researchers have identified the origin of subset of autoantibodies that worsen lupus (Photo courtesy of Pexels)

Lupus Biomarker Testing Could Help Identify Patients That Need Early and Aggressive Treatment

Systemic lupus erythematosus (SLE) is an autoimmune disease that occurs when the body's antibodies, which usually protect against infections, attack healthy cells and proteins. These autoantibodies can... Read more


view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more


view channel
Image: Use of DBS samples can break barriers in hepatitis C diagnosis and treatment for populations at risk (Photo courtesy of Pexels)

DBS-Based Assay Effective in Hepatitis C Diagnosis and Treatment for At Risk Populations

In a bid to eliminate viral hepatitis as a public health threat by 2030, the World Health Organization (WHO) has put forth a proposed strategy. To this end, researchers at the Germans Trias i Pujol Research... Read more


view channel
Image: New research has opened a path for fast and accurate cancer diagnosis (Photo courtesy of Imagene)

AI-Based Image Analysis Software Profiles Cancer Biomarkers in Real Time

Lung cancer is the most widespread type of cancer worldwide, resulting in approximately 1.76 million fatalities annually. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses... Read more


view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more


view channel
Image: The global antimicrobial resistance diagnostics market size is expected to reach USD 5.7 billion by 2028 (Photo courtesy of Pexels)

Global Antimicrobial Resistance Diagnostics Market Driven by Increasing Hospital-Acquired Infections

Antimicrobial drugs are intended to counteract the harmful effects of microbes and promote a healthy life. However, their excessive use can result in the development of resistance, commonly referred to... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.